154 related articles for article (PubMed ID: 38280081)
41. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
43. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
[TBL] [Abstract][Full Text] [Related]
45. [Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells].
Xiao X; Yuan T; Meng JX; Jiang YY; Cao YQ; Li Q; Sun R; Zhao MF
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(8):593-598. PubMed ID: 32164113
[No Abstract] [Full Text] [Related]
46. Exploring the Dilemma of Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy: To Transplant or Not?
Bouziana S; Bouzianas D
Biol Blood Marrow Transplant; 2020 Aug; 26(8):e183-e191. PubMed ID: 32304874
[TBL] [Abstract][Full Text] [Related]
47. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
[TBL] [Abstract][Full Text] [Related]
48. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
[No Abstract] [Full Text] [Related]
49. Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL.
Aldoss I; Khaled SK; Wang X; Palmer J; Wang Y; Wagner JR; Clark MC; Simpson J; Paul J; Vyas V; Chien SH; Stein A; Pullarkat V; Salhotra A; Al Malki MM; Aribi A; Sandhu K; Thomas SH; Budde LE; Marcucci G; Brown CE; Forman SJ
Clin Cancer Res; 2023 Feb; 29(4):742-753. PubMed ID: 36255386
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and Safety of Dual-Targeting Chimeric Antigen Receptor-T Therapy for Relapsed or Refractory B Cell Lymphoid Malignancies: A Systematic Review and Meta-Analysis.
Yu M; Zhang Q; Kong F; Qi L; Pu Y; Qiu L; Wang J; Li F
Hum Gene Ther; 2023 Mar; 34(5-6):192-202. PubMed ID: 36734417
[TBL] [Abstract][Full Text] [Related]
51. CAR T-cell therapy for B-cell lymphoma.
Denlinger N; Bond D; Jaglowski S
Curr Probl Cancer; 2022 Feb; 46(1):100826. PubMed ID: 35012754
[TBL] [Abstract][Full Text] [Related]
52. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy.
Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q
Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690
[TBL] [Abstract][Full Text] [Related]
53. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
Front Immunol; 2021; 12():681984. PubMed ID: 34248965
[TBL] [Abstract][Full Text] [Related]
54. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
55. A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells.
Fergusson NJ; Adeel K; Kekre N; Atkins H; Hay KA
Front Immunol; 2023; 14():1178403. PubMed ID: 37180149
[TBL] [Abstract][Full Text] [Related]
56. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
[No Abstract] [Full Text] [Related]
57. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.
Cao Y; Lu W; Sun R; Jin X; Cheng L; He X; Wang L; Yuan T; Lyu C; Zhao M
Front Oncol; 2019; 9():767. PubMed ID: 31482064
[TBL] [Abstract][Full Text] [Related]
58. Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells.
Xu Q; Xue L; An F; Xu H; Wang L; Geng L; Zhang X; Song K; Yao W; Wan X; Tong J; Liu H; Liu X; Zhu X; Zhai Z; Sun Z; Wang X
Front Immunol; 2022; 13():879030. PubMed ID: 35558072
[TBL] [Abstract][Full Text] [Related]
59. CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma.
Cheng Q; Tan J; Liu R; Kang L; Zhang Y; Wang E; Li Y; Zhang J; Xiao H; Xu N; Li M; Yu L; Li X
Cytotherapy; 2022 Oct; 24(10):1026-1034. PubMed ID: 35691818
[TBL] [Abstract][Full Text] [Related]
60. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL.
Zurko J; Nizamuddin I; Epperla N; David K; Cohen JB; Moyo TK; Ollila T; Hess B; Roy I; Ferdman R; Liu J; Chowdhury SM; Romancik J; Bhansali RS; Harris EI; Sorrell M; Masel R; Kittai AS; Denlinger N; Sigmund AM; Fitzgerald L; Galvez C; Ma S; Winter J; Pro B; Gordon LI; Danilov A; Stephens D; Shah NN; Kenkre V; Barta SK; Torka P; Shouse G; Karmali R
Blood Adv; 2023 Jun; 7(12):2657-2669. PubMed ID: 36094847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]